Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
O
226950
vs
K
KOSPI 200
Over the past 12 months, OliX Pharmaceuticals Inc has underperformed KOSPI 200, delivering a return of +27% compared to KOSPI 200's +116% growth.
Stocks Performance
226950 vs KOSPI 200
Performance Gap
226950 vs KOSPI 200
Performance By Year
226950 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
OliX Pharmaceuticals Inc
Glance View
OliX Pharmaceuticals is a drug development company that works on RNA interference, or RNAi, medicines. These are therapies designed to turn down harmful genes that help cause disease. The company mainly builds experimental drugs for conditions such as eye diseases, fibrotic diseases, and other hard-to-treat disorders. Its customers are not ordinary patients at the start. OliX sells its value to larger drugmakers, research partners, and eventually healthcare providers through approved medicines. It makes money mainly by developing drug candidates, licensing them to partners, and sharing in future milestones or royalties if those programs succeed. What makes OliX different is its focus on RNAi as a way to silence disease-causing genes rather than just treating symptoms. That puts it in the early-stage biotech part of the industry, where the main job is to discover, test, and partner on new medicines before they reach the market.